|
2008 Psychoeducation Workshops |
 |
Toronto, ON
Wednesday, Junuary 16, 2008 |
2007 Psychoeducation Workshops |
 |
Montreal, QC Friday, April 27, 2007
|
 |
Vancouver, BC Saturday, April 14, 2007 |
CANMAT
Bipolar Updates at
CPA CPD Institute: Collaborative Forums in Mental Health |
 |
Ottawa, ON
Friday, March 30, 2007 |
 |
Halifax, NS
Friday, April 27, 2007 |
 |
Vancouver, BC Friday, May 4
2007 |
 |
Montreal, QC Friday, June 1, 2007 |
 |
Toronto, ON Friday, June 8, 2007 |
|
| |
|
|
 |
 |
| |
|
CONTINUATION PHASE
TREATMENT (see
algorithm)
Acute phase treatment can last from 2-10 weeks, and the end of the acute
phase is defined as a point when the patient reverts to euthymia and where
the psychotic symptoms are resolved.
The acute phase of treatment presents opportunities for psychoeducation
of family and friends, and building a collaborative therapeutic relationship
with the patient. The patient is often only able to tolerate and digest
focal bits of psychoeducational information during the acute phase.
Significant psychoeducational and psychotherapeutic interventions commonly,
and appropriately, occur in the continuation phase (also called the early
stable phase) which lasts for a further 6-12 weeks. Normalization of biological
and social rhythms is an essential part of management too. Mood stabilizers
are the mainstay of pharmacoltherapy. Neuroleptics and benzodiazepines,
used for acute behavioural suppression or for rapid control of manic behavioral
dyscontrol, need to be gradually discontinued over 2-3 weeks after symptom
control has been achieved. Neuroleptics need to be continued well beyond
the acute phase only if there is persistent or incongruent psychotic symptoms.
Similarly, antidepressants can be gradually discontinued over 6-12 weeks
after remission from bipolar depression provided that the patient continues
to be on a mood stabilizer. However, if there is a previous history of
the patients symptoms being exacerbated every time neuroleptics,
antidepressants or other psychotropic medications are discontinued, there
is justification in continuing these medications in addition to mood stabilizers
during this phase and beyond. The clinician and patient should constantly
weigh the benefits versus risks of continuing or discontinuing treatments.
This is also the phase for active discussion with the patient and family
about long term treatment and the benefits and risks of prophylactic treatment.
Serum medication levels and monitoring/investigations of bodily systems
should be done as clinically indicated in the continuation phase.
|
|
|
|
 |